Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novo-Nordisk A/S

62.63
+1.332.17%
Post-market: 62.750.1199+0.19%19:59 EDT
Volume:7.89M
Turnover:492.25M
Market Cap:278.02B
PE:19.94
High:62.74
Open:62.48
Low:61.84
Close:61.30
Loading ...

Novo Nordisk (NVO): Among the Best Diabetes Stocks to Buy According to Billionaires

Insider Monkey
·
19 Mar

Novo Nordisk A/S Stock Rises Tuesday, Outperforms Market

Dow Jones
·
19 Mar

NVO vs. LLY: Which Stock Is the Better Value Option?

Zacks
·
17 Mar

European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading

MT Newswires Live
·
17 Mar

Novo Nordisk (0QIU) Gets a Buy from UBS

TIPRANKS
·
14 Mar

Zacks Market Edge Highlights: Tesla, NVIDIA, JPMorgan Chase, Exxon Mobil and Novo Nordisk

Zacks
·
14 Mar

An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup

Quartz
·
14 Mar

Novo Nordisk (NVO) Gains As Market Dips: What You Should Know

Zacks
·
14 Mar

NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand

Zacks
·
14 Mar

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

Zacks
·
14 Mar

Novo Nordisk A/S Stock Rises Thursday, Outperforms Market

Dow Jones
·
14 Mar

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy

TIPRANKS
·
14 Mar

Novo Nordisk put volume heavy and directionally bearish

TIPRANKS
·
13 Mar

European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading

MT Newswires Live
·
13 Mar

How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma

Zacks
·
13 Mar

Novo Nordisk Shares Rebound 4% After A 14% Plunge Over Three Trading Days

Tiger Newspress
·
13 Mar

NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study

Zacks
·
12 Mar

Novo Nordisk's CagriSema Trial Shows Disappointing Weight Loss -- Market Talk

Dow Jones
·
11 Mar

Novo Nordisk's CagriSema Results Fail to Impress -- Market Talk

Dow Jones
·
11 Mar

Positive Outlook for Novo Nordisk: Strong Data, Expertise, and Next-Gen Developments Drive Buy Rating

TIPRANKS
·
11 Mar